Zusduri (mitomycin)
Intravesical Kit
Last reviewed · Source: First Databank (FDB) drug data
Overview
Mitomycin is an antineoplastic antibiotic produced by Streptomyces caespitosus.
USES: This medication is used to treat a certain type of cancer (bladder cancer). It works by slowing or stopping the growth of cancer cells.
Generic name: mitomycin
Pronunciation: (MYE-toe-MYE-sin)
Therapeutic class: Antineoplastics
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Zusduri
Indications
The following indications are listed for Zusduri:
- Non-Muscle Invasive Bladder Cancer
Also known as: Superficial Carcinoma Of Urinary Bladder.
Dosing
Dosage of mitomycin must be based on the clinical and hematologic response and tolerance of the patient and whether other myelosuppressive therapy is also being used to obtain optimum therapeutic results with minimum adverse effects. Clinicians should consult published protocols for the dosage of mitomycin and other chemotherapeutic agents and the method and sequence of administration.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Zusduri 40 Mg Vial | Maintenance | Instill 75 mg by intravesical route once weekly for 6 weeks. |
| Zusduri Single-Dose Kt(40Mgx2) | Maintenance | Instill 75 mg by intravesical route once weekly for 6 weeks. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Lactation
- Rupture of bladder
- Increased risk of bleeding due to coagulation disorder
- Pregnancy
- Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min
- Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Urethral stricture
- Urinary retention
More Frequent
- Abnormal hepatic function tests
- Anemia
- Dysuria
- Eosinophilia
- Hematuria
- Hyperkalemia
- Kidney disease with reduction in glomerular filtration rate (GFr)
- Lymphopenia
- Neutropenic disorder
- Urinary tract infection
Less Frequent
- Balanitis
- Edema of male genital organs
- Fatigue
- Genital organ pruritus
- Increased urinary frequency
- Pain in penis
- Swelling of vagina
- Urethritis
- Urinary incontinence
- Urinary urgency
- Vulvovaginal pain
Precautions
No enhanced messaging available.
No enhanced messaging available.
Mitomycin has produced teratogenic effects in animals. Safe use of mitomycin in pregnant women has not been established.
It is not known whether mitomycin is distributed in milk. Because of the potential for serious adverse reactions to mitomycin in nursing infants, nursing should be discontinued during mitomycin therapy.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Non-muscle invasive bladder cancer | ||
| C67.9 | ICD10CM | Malignant neoplasm of bladder, unspecified |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.